

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Karl Herman SCHLINGENSIEPEN et al.

Serial No.: 09/701,583

Filed: February 5, 2001

For: A METHOD FOR STIMULATING THE IMMUNE SYSTEM

**RESPONSE TO NOTICE TO FILE MISSING PARTS OF
APPLICATION UNDER 37 C.F.R. §1.53**



Examiner: Unassigned

Group Art Unit: 1632

RECEIVED

JUL 02 2003

TECH CENTER 1600/2900

Commissioner of Patents
Washington, D.C. 20231

**Attention: APPLICATION BRANCH
MISSING PARTS OF APPLICATION**

Sir:

In response to the Notice To File Missing Parts mailed July 24, 2001, copy attached, attached hereto is:

- Amendment and Response to Notice to Comply with Sequence Rules
- Petition for Extension of Time.
- Preliminary Amendment.
- Basic Filing Fee and Surcharge.

	<u>Small Entity</u>	<u>Large Entity</u>	
Basic Filing Fee	\$355	\$710	= \$710.00
Total Claims <u> </u> - 20 = 0	\$9	\$18	= \$
Indep. Claims <u> </u> - 3 = 0	\$40	\$ 80	= \$
<u> </u> Surcharge - Late Filing	\$65	\$130	= \$130.00
<u> </u> Extension Fee under 37 CFR §1.17			= \$
TOTAL FILING FEES	\$0.00		

The Commissioner is hereby authorized as set forth in §1.16 or §1.17 to debit Deposit Account No. 06-1358 as needed in order to effect proper filing of the application.

Respectfully submitted,

By: William E. Player
William E. Player
Reg. No. 31,409

JACOBSON HOLMAN PLLC
400 Seventh Street, N.W.
Washington, D.C. 20004-2201
(202) 638-6666
Date: September 24, 2001

William E. Player
COPY



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT
United States Patent and Trademark Office
Washington, D.C. 20231
www.uspto.gov

U.S. APPLICATION NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/701583	SCHLINGENSIEPEN	K P66141US0
INTERNATIONAL APPLICATION NO.		
PCT/EP99/04013		
TA. FILING DATE	PRIORITY DATE	
10 JUN 99	10 JUN 98	
DATE MAILED		
24 JUL 2001		

JACOBSON HOLMAN PLLC
400 SEVENTH STREET N.W.
SUITE 600
WASHINGTON, DC 20004



**NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant has submitted papers under 35 U.S.C. 371 to enter the national stage in the United States of America. The items indicated below, however, are missing. The period within which to correct the deficiency noted below and avoid abandonment is set forth in the accompanying Notification.

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

The application fails to comply with the requirements of 37 CFR 1.821-1.825.

This application does not contain, a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).

A copy of the "Sequence Listing" in computer readable format has not been submitted as required by 37 CFR 1.821(e).

A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."

The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).

The paper copy or compact disc of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).

Other: _____

APPLICANT MUST PROVIDE:

An initial or substitute computer readable form (CRF) of the "Sequence Listing."

An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.

A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE
CALL:

(703) 308-4216, for Rules interpretation,
(703) 308-4212, for CRF submission help,
(703) 287-0200, for PatentIn software help.

Deborah D. Williams

Telephone: 703-305-3744

RECEIVE
JUL 02 2003
TECH CENTER 1600/2900

COPY



Atty. Dkt. No. P66141US0

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Karl Herman SCHLINGENSIEPEN et al.

Serial No.: 09/701,583

Examiner: Unassigned

Filed: February 5, 2001

Group Art Unit: 1632

For: A METHOD FOR STIMULATING THE IMMUNE SYSTEM

RESPONSE TO NOTICE TO COMPLY WITH SEQUENCE RULES

Commissioner of Patents
Washington, D.C. 20231

Sir:

In accordance with the Notice to Comply with sequence rules 37 CFR 1.821 – 1.825, a copy of which is attached, hereto, applicant submits, herewith a substitute:


- (1) Computer Readable Form (CRF) of Sequence Listing; and
- (2) Substitute paper copy of Sequence Listing.

The content of the computer readable form and the paper copy are the same and, where applicable, include no new matter, as required by 37 CFR § 1.821(e), § 1.821(f), § 1.821(g), § 1.825(b), or 1.825(d).

Favorable action is requested.

Respectfully submitted,

By


William E. Player
Registration No. 31,409

Date: September 24, 2001

JACOBSON HOLMAN PLLC
400 Seventh Street, N.W.
Washington, D.C. 20004
Telephone: (202) 638-6666
Atty. Docket No.: P66141US0
WEP/vjb

R:\HOME\WBYERS\2001\September\P66141US0-Resp to Not to Comply.wpd

RECEIVED
JUL 02 2003
TECH CENTER 1600/2900